<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04651179</url>
  </required_header>
  <id_info>
    <org_study_id>OSTEOREC/OSS</org_study_id>
    <nct_id>NCT04651179</nct_id>
  </id_info>
  <brief_title>Study of Effectiveness of GEMDOX in Relapsed Osteosarcoma</brief_title>
  <official_title>A Retrospective Observational Study of the Effectiveness of Gemcitabine -Docetaxel in Patients With Relapsed Osteosarcoma Who Have Been Treated With HD-IFO in First Line Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Azienda Ospedaliera Ospedale Infantile Regina Margherita Sant'Anna</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Azienda Ospedaliera Ospedale Infantile Regina Margherita Sant'Anna</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A retrospective observational study of the effectiveness of gemcitabine - docetaxel in&#xD;
      patients with relapsed osteosarcoma who have been treated with HD IFO in first line treatment&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 24, 2020</start_date>
  <completion_date type="Anticipated">September 30, 2021</completion_date>
  <primary_completion_date type="Actual">June 6, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Response to Gemcitabina - Docetaxel Treatment</measure>
    <time_frame>12 months</time_frame>
    <description>assessed as overall survival (12 months)</description>
  </primary_outcome>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Osteosarcoma Recurrent</condition>
  <condition>Osteosarcoma Metastatic</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>observation</intervention_name>
    <description>not applicable, observational study</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        patients with relapsed osteosarcoma treated with gemcitabine- docetaxel after a first line&#xD;
        with HD- IFO&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age at diagnosis of high grade osteosarcoma &gt;= 4&#xD;
&#xD;
          -  Received first line treatment with HD IFO&#xD;
&#xD;
          -  Following HD IFO treatment, they have been diagnosed refractory disease and they&#xD;
             satisfy at least one of the following criteria :&#xD;
&#xD;
               1. Relapsed in the first 24 month following the initial diagnosis, regardless of&#xD;
                  location and resectability&#xD;
&#xD;
               2. Lung relapsed disease with more than 2 nodules diagnosed over 24 months from the&#xD;
                  initial diagnosis&#xD;
&#xD;
               3. Non resectable relapsed disease diagnosed over 24 months from the initial&#xD;
                  diagnosis Before or during GEMDOX treatment, eligible patients may have been&#xD;
                  subject to metastasectomy&#xD;
&#xD;
        Exclusion Criteria: none&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>4 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Franca Fagioli, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>AOU Città della Salute e della Scienza di Torino - Presidio Infantile Regina Margherita</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sebastian Asaftei, MD</last_name>
    <phone>0039011693</phone>
    <phone_ext>7150</phone_ext>
    <email>sebastiandorinasaftei@unito.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Celeste Cagnazzo, PhD</last_name>
    <phone>0039011693</phone>
    <phone_ext>7150</phone_ext>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Istituto Nazionale Tumori</name>
      <address>
        <city>Milan</city>
        <state>Milano</state>
        <zip>20133</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Fondazione del Piemonte per l' Oncologia IRCCS Candiolo</name>
      <address>
        <city>Candiolo</city>
        <state>Turin</state>
        <zip>10060</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giovanni Grignani</last_name>
      <email>giovanni.grignani@ircc.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Istituto Ortopedico Rizzoli</name>
      <address>
        <city>Bologna</city>
        <zip>40136</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>AOUC Azienda Ospedaliero-Universitaria Careggi</name>
      <address>
        <city>Florence</city>
        <zip>50134</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>IRCCS Istituto Nazionale dei Tumori</name>
      <address>
        <city>Milan</city>
        <zip>20133</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero Universitaria pisana</name>
      <address>
        <city>Pisa</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>IRCCS Istituti Fisioterapici Ospitalieri</name>
      <address>
        <city>Rome</city>
        <zip>00144</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>AOU Città della Salute e della Scienza di Torino - Presidio Infantile Regina Margherita</name>
      <address>
        <city>Turin</city>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>November 24, 2020</study_first_submitted>
  <study_first_submitted_qc>December 2, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 3, 2020</study_first_posted>
  <last_update_submitted>July 30, 2021</last_update_submitted>
  <last_update_submitted_qc>July 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Azienda Ospedaliera Ospedale Infantile Regina Margherita Sant'Anna</investigator_affiliation>
    <investigator_full_name>Prof. Franca Fagioli</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteosarcoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

